Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Agenus, Inc. - "2015: Poised To Be Another Transformative Year for Agenus"

AGEN

NEW YORK, NY / ACCESSWIRE / January 12, 2015 / Agenus, Inc. (NASDAQ: AGEN) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Garo Armen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog Dr. Armen provides details on the recently announced partnership with Incyte Corporation, and speaks to the compelling strategic rationale for the global immuno-oncology alliance. Additionally, he recaps an exciting close to 2014 and describes 2015's potential for being a transformative year for Agenus. Read the full blog post from Dr. Garo Armen on TheChairmansBlog.com (http://www.thechairmansblog.com/agenus/garo-armen/2015-poised-another-transformative-year-agenus).

About Agenus

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and adjuvants. Agenus' checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company's proprietary discovery engine Retrocyte DisplayTM is used to generate fully human and humanized therapeutic antibody drug candidates. The Retrocyte DisplayTM platform uses a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. Agenus' heat shock protein-based vaccines for cancer and infectious disease have completed Phase 2 studies in glioblastoma multiforme, and in the treatment of herpes simplex viral infection. The company's QS-21 Stimulon(R) adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen Sciences Ireland UC and includes several vaccine candidates in Phase 2, as well as shingles and malaria vaccines which have successfully completed Phase 3 clinical trials. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.


SOURCE:
The Chairman's Blog



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today